All studies
Cardiology · Registry · Sweden
Matthews 2021
Myocardial infarction
PPSuperiorityAcademia3/5 disclosures
Comparisons
4
In the analysis
0
4 withheld
Target trials
1
Emulations reported
2
2 treatments
Design and methods
- Estimand
- PP
- Design hypothesis
- Superiority
- Matching / weighting
- IPTW, Outcome regression followed by standardization
- Analysis method
- Pooled logistic regression models with flexible time-varying intercept
- Missing data
- Median imputation + Assumed no exposure
- Covariates adjusted
- 21
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Registry
- Data sources
- 1
- Geography
- Sweden
- Eligible sample
- 4940
- Treated
- 2634
- Control
- 2306
- Emulations
- 2
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- https://doi.org/10.1101/2021.02.01.21250739
- Data availability
- Unavailable
- Code availability
- https://github.com/tonymatthews/validate
- Conflicts of interest
- Declared: Industry
- COI institutions
- AstraZeneca, Cytel, ProPublica
- Funding
- Declared: Public
- Funders
- Swedish Research Council
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2021_Matthews_MyocardialInfarction
- DOI
- https://doi.org/10.1161/jaha.120.020357
- Affiliations
- Karolinska Institutet, Karolinska University Hospital, Harvard T.H. Chan School of Public Health, Uppsala University, Lund University, Skåne University Hospital, Danderyd University Hospital, Harvard-MIT
- Sector
- Academia
- Target trials (study level)
- VALIDATE-SWEDEHEART
- Registration
- NCT02311231